– New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – – DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
(Nasdaq: CPIX ), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in liabilities and $25 million of shareholders' equity.
"With a number of developments and growth opportunities underway at Cumberland , we remain optimistic about our future outlook," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals.
"As we move into the remainder of the year, our dedicated team will continue in their efforts – working together to provide unique products that improve the quality of patient care." RECENT DEVELOPMENTS INCLUDE: New Real-World Study Favors Caldolor over ketorolac Earlier this week, Cumberland announced the publication of new real-world outcomes research comparing Caldolor to its key competitor – ketorolac. This extensive analysis evaluated 17 million patient records and selected over 150,000 adult and pediatric patients who receive either product.
The results provide compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions and also improved healthcare utilization. Cumberl.